ERBB2 and breast cancer: Approximately 15% of sporadic breast cancers are categorized into the basal-like subtype that expresses basal/myoepithelial cell markers, but does not express estrogen receptor (ER), progesterone receptor (PR), or HER2 [1-3], and is associated with poor prognosis.